GlobeNewswire

Crystal Ravel Christened In Budapest

Dela

Miami, FL, July 11, 2018 (GLOBE NEWSWIRE) -- Less than two years ago, Crystal launched its first river ship, Crystal Mozart, marking the company's grand entrance into Europe's river cruising industry. Today, Crystal River Cruises welcomed its fifth ship and the newest member of the fleet, Crystal Ravel, during a christening ceremony in Budapest, Hungary. The World's Most Luxurious River Cruise Line(TM) celebrated the occasion with Crystal's President and CEO Tom Wolber; the ship's godmother, Hungarian philanthropist and creator of the hit "Virtuosos" classical music talent show, Mariann Peller; and Crystal River Cruises' Vice President and Managing Director Walter Littlejohn.

"Today is a proud day for the entire Crystal family. In just over two years, we introduced five ships, which is a tremendous accomplishment of growth for this expansion of the Crystal brand," Wolber said. "But what makes us most proud is that with each new ship and new experience, Crystal's commitment to superb quality and exceptional luxury and service has remained unwavering."

Crystal River Cruises now comprises Crystal Ravel and her identical sister ships: Crystal Bach, Crystal Mahler and Crystal Debussy; as well as Crystal Mozart, which at twice the width of any other river cruise ship, is Europe's most spacious river cruise ship and launched the brand in July 2016.

 "Beyond these exquisite ships - which are earning the acclaim of luxury travelers from around the world - the heart of the Crystal River Experience is the people," Littlejohn said. "Crystal's crew is simply unmatched in their warm, genuine service and attention to detail. Our guests are savvy travelers who truly value that personal connection and frequently share the sentiment that sailing with Crystal is like coming home to their onboard family."

"To be named the godmother of a ship that celebrates the classical musical heritage of this country and the lands that surround her - is an honor that speaks to my heart," Peller said. "Beyond the connection to the musical masters of this region, Crystal River ships represent the stunning grace, elegance and beauty of the rivers that flow here. I am honored to become part of the Crystal Family, as this company embodies a dedication to excellence."

Tenor Steffan Mullan performed during the ceremony, while Young Virtuosos artists performed aboard the ship following the traditional blessing, including clarinetist Ali Dániel Lugosi, double bassist Tamás Kökény, violinist Amira Abouzahra, violinist Mariam Abuzahra, and Budapest Festival Orchestra harpist Ágnes Polonyi with a special performance onboard the ship.

The ceremony took place during the ship's overnight stay in Budapest on its weeklong "Danube Serenade" voyage, allowing guests aboard the sailing to participate in the festivities, while Crystal crew members also looked on from the decks of the ship. Travelers from around the world joined the celebration via the Facebook Live broadcast on Crystal's Facebook page.

Crystal Ravel is currently sailing itineraries of six to 14 days between Vienna and Basel; and in 2019 she will be the only river ship to sail seven-night Danube cruises round-trip from Vienna to ports in Austria, Hungary and Slovakia.

Crystal's new river vessels are the river cruising industry's first and only all-balcony, all-suite, all-butler vessels in Europe, with every category of accommodation positioned above the water line.  All suites feature Panoramic Balcony-Windows(TM) and walk-in closets and dual vanity in the bathrooms are featured in most categories. Crystal Mozart is Europe's most spacious river ship, at twice the width of any other, and offers an unrivalled number of social spaces, restaurants and the largest spa on the rivers. All of Crystal's river ships feature acclaimed butler service in every room category, king-sized beds, ETRO amenities, robes and slippers, and wall-mounted flat-screen HD TVs. Additional enticing features include farm-to-table cuisine in multiple, open-seating eateries: the elegant Waterside Restaurant, namesake Bistro cafés and the exclusive Vintage Room; and the Palm Court for entertainment, enrichment presentations and sweeping views of the countryside.

About Crystal

The world-renowned Crystal Experience - featuring global journeys with Crystal Cruises, Crystal River Cruises, Crystal Yacht Expedition Cruises, Crystal AirCruises and Crystal Luxury Air - continues to be the distinctive choice of the world's most discerning travelers. Crystal Cruises is the World's Most Awarded Luxury Cruise Line, having earned "World's Best Cruise Ship" in Condé Nast Traveler's Reader Choice Awards and been voted "World's Best Large Ship Cruise Line" by Travel + Leisure readers more than any cruise line, hotel or resort in history; and the "Best Luxury Cruise Line" by travel professional organization Virtuoso for three consecutive years (2014, 2015 & 2016). The readers of Travel + Leisure also voted Crystal River Cruises the "World's Best River Cruise Line" and Crystal Yacht Expedition Cruises the "World's Best Small-Ship Cruise Line" in 2017. Crystal is proud to be a platinum partner of ASTA.

For more information and Crystal reservations, contact a travel professional, call 888.799.2437, or visit www.crystalcruises.com. Join the hundreds of thousands who subscribe to the Crystal Insider blog, follow Crystal Cruises' Facebook page and @crystalcruises on Twitter and Instagram, and engage in the conversation with #crystalcruises.

###

Attachments

Media Relations
Crystal Cruises
3102034305
mediarelations@crystalcruises.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crystal Cruises via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum